Soft sales in its core product, a 25% plunge in another core revenue driver, and a narrowed 2025 sales outlook are red flags. Did Merck’s earnings deliver a bearish catalyst?
Record earnings per share with oil prices at current levels, excellent cash flow from operations, and a healthy dividend yield. Is Exxon Mobil a buy after stellar earnings?